English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background —Although aprotinin is known to be effective in reducing postoperative hemorrhage after cardiac surgery, ε-aminocaproic acid, an alternative antifibrinolytic, is considerably less expensive. Because the results of 3 small randomized clinical trials comparing these 2 agents directly were inconclusive, we performed a meta-analysis to compare the relative effectiveness and adverse-effect profile of these 2 agents against placebo.Methods and Results —Data from 52 randomized clinical trials published between 1985 and 1998 involving the use of ε-aminocaproic acid (n=9) or aprotinin (n=46) in patients undergoing cardiac surgery were abstracted. Our primary outcomes were total blood loss, red blood cell transfusion rates and amounts, reexploration, stroke, myocardial infarction, and mortality. The meta-analysis revealed substantial reductions in total blood loss with ε-aminocaproic acid and low-dose aprotinin (each with a 35% reduction versus placebo,P &lt;0.001) and high-dose aprotinin (53% reduction,P &lt;0.001). There were identical reductions in total postoperative transfusions with ε-aminocaproic acid (61% reduction versus placebo,P &lt;0.010) and high-dose aprotinin (62% reduction,P &lt;0.001). The proportion of patients transfused was similarly reduced with ε-aminocaproic acid (OR, 0.32; 95% CI, 0.15 to 0.69) and high-dose aprotinin (OR, 0.28; 0.22 to 0.37). Although both drugs reduced rates of reexploration to similar degrees, this effect was statistically significant only with high-dose aprotinin (OR, 0.39; 0.24 to 0.61). ε-Aminocaproic acid and aprotinin had no effect on risks of postoperative myocardial infarction or overall mortality.Conclusions —Because the 2 antifibrinolytic agents appear to have similar efficacies, the considerably less-expensive ε-aminocaproic acid may be preferred over aprotinin for reducing hemorrhage with cardiac surgery.

Is ε-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery?